Dr. Eduardo B. Fernandez

  • Radiation Oncologist
  • Spoken languages English, Spanish


Career Positions

Current position(s)

  • GenesisCare - National Medical Director, Plantation, FL

Past position(s)

  • American College of Radiation Oncology - Vice President and Board of Chancellors
  • Aventura Hospital - Chief of Radiation Oncology, Aventura, FL
  • Cleveland Clinic Florida - Head of Radiation Oncology, Dual Appointment at Main Campus of Cleveland Clinic Foundation, Weston, FL



  • University of Malaga (European Union), PhD, Malaga, Spain
  • University of Malaga (European Union), Doctor of Medicine, Malaga, Spain


  • Cleveland Clinic Foundation, Radiation Oncology, Cleveland, OH


  • Cleveland Clinic Foundation, Medical, Surgical, Cleveland, OH

Expertise And Interests


  • Prostate, Breast, Lung, Colorectal, Head and Neck, Brain and Spine Tumors


Awards and honors

  • Multicultural Leadership Award - Florida Diversity Council; Honorary Member of the Radiation Therapy Society of the Dominican Republic; Leader in Medicine Award - Florida Medical Association; Distinguished Physician - Florida Medical Association; Two doct


  • Protection by Fluoride against Phthalocyanine induced photodynamic killing of Chinese Hamster Cells
  • Comparative Study of Ion F-Mediated Inhibition on Nuclear DNA Photodynamic Damage Induced by Dihematoporphyryn Ether and Chloro-aluminum-phthalocyanine in V-79 Cells
  • Analysis of Toxicity In a Group of Patients Treated for Pancreatic Cancer with Combined Modality 3-D Radiation Therapy
Expand Publications
View 1 more



Dioval A. Remonde, BS, Ron R. Allison,MD, Sharon A. Salenius, MPH, Andrej Hnatov, MD, Cynthia Ballenger, MD, Constantine A. Mantz, MD, Eduardo Fernandez,MD,PhD, Steven E. Finkelstein,MD, 2015, ARS

View Presentation


Francisco A. Myslicki, Jesse Shulman, Sharon Salenius, Neal Shore, Constantine Mantz, Eduardo Fernandez, Steven E. Finkelstein, 20158, ARS

View Presentation


Lacombe J, McClain K, Gonzales P, Fernandez E, Galmarini D, Dosoretz D, Zenhausern F, Finkelstein SE., 2016, ACRO

View Presentation


E. Arrojo, E. Fernandez, L. Kestin, A. Martinez., 2016, ACRO

View Presentation


Finkelstein SE, Salenius S, Cross CK, Allison RR, Shafman T, Mantz C, Fernandez E, 2016, ASCO

View Presentation


Finkelstein SE, Forman J, Fernandez E, Chen C, Lieberfarb M, Salenius SA, Shafman T, and Mantz CA, 2016, ASTRO

View Presentation


Martinez A, Olivera G, Ghilezan M, Forman J, Kestin L, Finkelstein S, Mo X, Key S, Mantz C, Fernandez E, Galmarini D, et al., 2015, ASTRO Annual Meeting

View Presentation


Myslicki FA, Salenius SA, Rotterman YW, Mantz CA, Finkelstein SE, Fernandez E., 2015, ACRO Annual Meeting

View Presentation


Allison R, Salenius SA, Hnatov A, Ballenger D, Lichtblau D, Mantz CA, Fernandez E, Finkelstein SE, 2015, ASTRO Annual Meeting

View Presentation


Kestin L, Fernandez E, Mantz C, Olivera G, Mo X, Key S, Finkelstein SE, Martinez A, Galmarini D., 2015, ASTRO Annual Meeting

View Presentation


A. Ahamad, S. Salenius, R. Ross, E. Fernandez, 2016, ASTRO

View Presentation


Anesa W. Ahamad, Sharon Salenius, Chaundre K. Cross, Ron R. Allison, Eduardo B. Fernandez, 2016, ACRO

View Presentation


Mantz Constantine, Wallner Paul, Fernandez Eduardo B., Salenius Sharon, 2017, AAPM Spring Clinical Meeting

View Presentation


Ron R. Allison, Sharon A. Salenius, Andrej Hnatov, Cynthia Ballenger, Anesa Ahamad, Constantine A. Mantz, Eduardo Fernandez, Steven E. Finkelstein, 2016, American Radium Society 100th Anniversary Meeting

View Presentation


Anesa Ahamad, Donald Weed, Darel Pruett, Daniel Saulpaugh, Eduardo Fernandez, 2016, American Radium Society’s 100th Anniversary Meeting

View Presentation


Myslicki FA, Salenius SA, Shore ND, Mantz CA, Fernandez E, Finkelstein SE, 2015, ACRO Annual Meeting

View Presentation
Expand Presentations
View 14 more

Clinical studies

Primary Objective - To determine whether men with NCCN high risk prostate cancer who are in the lower 2/3 of Decipher genomic risk (< 0.85) can be treated with 12 months ADT plus RT instead of 24 months ADT+RT and experience non-inferior metastasis-free survival.

View Study

Eduardo Fernandez-Vicioso's Reviews


based on 86 Ratings 20 Comments


The reception was excellent, take all my fears


Provide more time to address questions


Accommodations to transfer my mother from her wheel chair to the exam table.


The only problem with the provider is actually not the provider himself, but hi staff that did not explain any additional charges. So co-payments which I had to pay prior to starting the treatment and that is unacceptable because I may not have the funds or whatever other situation I may have. So it's very important to inform the patient of every possible of every possibility of additional charges or any kind of deductible payments or anything of that nature. Otherwise, everything was excellent. Thank you.

Read More

Ratings and Comments Powered by NRC Health